A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
Clinical trial NCT05200312 · UNKNOWN
Trial details
- NCT number
- NCT05200312
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-01
- Primary completion
- 2024-02-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.